Polynucleotide consultation: product, evidence and suitability

The first question in the polynucleotide consultation is which product is recommended for which skin target. Disclosure of ingredient source information and site-specific evidence provides more concrete information than making decisions based on a popular app name alone. This guide addresses questions that may be asked during the examination and the limits of expectation of PN.

Getting to know the product behind the PN name

The name polynucleotide or PN does not describe a single ingredient and standard session plan. During the consultation, the trade name, manufacturer, source material and instructions for use of the product being considered should be learned first. It would not be right to consider products prepared in different densities or with different ingredients as equivalent just because they are under the same title. A friend's experience is also not indicative of suitability for your skin, target area, or allergy history.

Embodying the expectation of skin quality

Describe what change you care about, rather than a broad expectation such as looking more vibrant. Fine line appearance, surface texture and sensitivity in a specific area are evaluated separately. While examining the skin, the physician also examines whether there is volume loss, significant laxity, or active skin disease. PN should not be considered for the purpose of creating significant volume, such as contour filler; Some expectations may require a different approach or just proper skin care.

Separating evidence from marketing statement

The fact that there is a published study about the product does not mean that the same results will be obtained in all regions. The product used in the study, the number of participants, the application method and the follow-up period may be asked during the consultation. Positive findings reported in small studies do not prove long-term safety or the same response in everyone. It is important to explain the current uncertainties rather than promising percentage regeneration, definitive rejuvenation or fixed effect duration. The date and observation by which the result will be evaluated should be determined at the beginning.

Sharing allergy and health history

If you are sensitive to ingredients, especially those originating from fish, report this before choosing the product; This is why knowing the source is important. Any widespread rash, persistent swelling, or nodule that develops after previous injections should also be shared. Active infection, pregnancy or breastfeeding, autoimmune diseases, and medications may affect the eligibility decision. Do not self-medicate. Examining the health history may lead some people to postpone the procedure or consider completely different options.

Determine the decision and follow-up conditions together

At the end of the consultation, not only the number of sessions recommended, but also the reason for this recommendation should be clear. Each check-up should revisit skin findings, undesirable effects, and your desire to continue. Possibilities such as swelling, bruising, infection, allergic reaction and permanent nodule should be discussed. Request that the product registration be recorded in your file and which physician to contact in case of unexpected symptoms. CNR Aesthetics can support consultation and appointment coordination; The medical practitioner determines medical suitability and the scope of the procedure.

During the PN meeting, it should be discussed not only whether the product is useful or not, but also whether it is necessary for your goal. For example, surface dryness and significant volume loss may occur together in the same person; It may not be possible to meet these two expectations with a single product. Before the meeting, get your priorities in order and explain what change makes sense for you. When comparing options, the physician may also consider the option of not taking action. Accepting scientific uncertainty allows you to make decisions without rushing. It is not necessary to give an injection immediately after the first meeting; You may want time to read the product information and ask questions again.

Does it replace PN filling?

Skin quality goals for PN are discussed. The expectation of significant volume or facial contour is evaluated differently; It should not be presented as if it belongs to the same product group.

Which document should I ask for at the consultation?

The full name of the product, source information, instructions for use and registration information are important. Evidence and follow-up plan for the targeted area should also be described.

Can the number of sessions be determined without examination?

A fixed number without personal evaluation is not the right decision criterion. The product instructions, the target and the skin's response are taken into account together.